Cytotoxic anti-lag-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease

ABSTRACT

Cytotoxic anti-LAG-3 monoclonal antibodies or fragments thereof causing depletion of LAG-3 +  activated T cells are described, as are related pharmaceuticals and methods of treating. Also described are related nucleic acid and protein sequences.

CROSS-REFERENCE TO RELATED APPLICATION

This application is a Continuation-in-part application of U.S.application Ser. No. 12/598,128, which was filed Oct. 29, 2009 and whichis a National Stage entry of International Application No.PCT/IB2008/001027, filed Apr. 30, 2008, which claims priority toEuropean Patent Application No. 07290545.8, filed Apr. 30, 2007, thedisclosures of which are incorporated by reference in their entirety.

FIELD OF THE INVENTION

The present invention is in the field of immunotherapy. Morespecifically, it relates to the treatment or prevention of organtransplant rejection or for treating autoimmune disease. The inventionrelates to molecule binding to LAG-3 protein and causing depletion ofLAG-3⁺ activated T cells. More specifically, it relates to cytotoxicLAG-3-specific monoclonal antibody or fragment thereof.

BACKGROUND

Lymphocyte activation gene-3 (LAG-3, CD223) is upregulated during theearly stages of T-cell activation. The present invention is based on theanalysis of the effects of cytotoxic antibodies against LAG-3 in acutecardiac allograft rejection (in vivo animal studies) and in in vitroexperiments where selected LAG-3 monoclonal antibodies are efficient atlow doses (<0.1 μg/ml) at depleting LAG-3+ activated effector T cells.

Selectively depleting activated T lymphocytes might represent animmunosuppressive induction treatment able to result in the developmentof regulatory cells supporting a long-term survival of allogeneic organsin mice and primates (1). This has actually been demonstrated withanti-CD40L antibodies that deplete in vivo activated T cells through aFc-dependent mechanism (2). However, anti-CD40L antibodies also targetactivated platelets in humans and affect the stability of arterialthrombi (3). Therefore the development of monoclonal antibodies to othermolecules specific for T-cell activation has catalyzed attempts toachieve immunosuppression. One such molecule is LAG-3, which engagesClass II on dendritic cells (DC) with a high affinity, enabling DC tobecome activated (4-6). The LAG-3 protein is expressed in vivo inactivated CD4⁺ and CD8⁺ lymphocytes residing in inflamed secondarylymphoid organs or tissues but not in spleen, thymus or blood (7). Inaddition, LAG-3 can function as a negative regulator of activated humanCD4 and CD8 T cells by inhibiting early events in primary activation(8).

SUMMARY OF THE INVENTION

The invention provides a molecule binding to LAG-3 protein and causingdepletion of LAG-3⁺ activated T cells. Said depletion can be measured bychanges in peripheral blood lymphocyte numbers, in a tissue or an organ.

In a preferred embodiment the molecule binding to LAG-3 protein is acytotoxic anti-LAG-3 monoclonal antibody or fragment thereof causingdepletion of LAG-3⁺ activated T cells, said antibody comprising an Fcfragment from the human IgGI or IgM (or mouse IgG2a) subclass and an Fabfragment which binds LAG-3 protein, said antibody exhibiting acomplement-dependant cytotoxicity (CDC) and/or an antibody dependantcell cytotoxicity activity (ADCC).

In one embodiment, the anti-LAG-3 monoclonal antibody is IMP731 or abiologically active fragment thereof.

Another aspect of the invention is a method of depleting LAG-3⁺activated T cells in a mammal, the method comprising administeringmonoclonal antibody IMP731 or a biologically active fragment thereof tosaid mammal.

Another embodiment of the invention is a pharmaceutical compositioncomprising monoclonal antibody IMP731 or a biologically active fragmentthereof.

Another embodiment of the invention is a method of treating diseasesassociated with LAG-3⁺ activated T cells in a subject, the methodcomprising administering an effective amount of a pharmaceuticalcomposition composing monoclonal antibody IMP731 or a biologicallyactive fragment thereof to said subject. Such disease may be anauto-immune disease. Exemplary auto-immune diseases include autoimmunehemolytic anemia, autoimmune thrombocytopenia purpura. Goodpasture'ssyndrome, pemphigus vulgaris, acuta rheumatic fever, mixed essentialcryoglobulinemia, systemic lupus erythematosus, insulin-dependentdiabetes mellitus, rheumatoid arthritis, Grave's disease, Hashimoto'sthyroiditis, myasthenia gravis, psoriasis and multiple sclerosis.

The present invention further provides a method for treating orpreventing organ transplant rejection or for treating auto-immunedisease. Said method comprises the administration, to a mammaliansubject, of a therapeutically effective amount of a cytotoxic anti-LAG-3monoclonal antibody or fragment thereof. In one embodiment, themonoclonal antibody is IMP731.

Another embodiment of the invention is directed to an isolated nucleicacid molecule comprising a nucleic acid sequence encoding the kapparegion of IMP731 or a biologically active fragment thereof.

Another embodiment is directed to a polypeptide encoded by a nucleicacid molecule comprising a nucleic acid sequence encoding the kapparegion of IMP731 or a biologically actve fragment thereof.

Another embodiment is directed to an isolated nucieic acid moleculecomprising a nucleic acid sequence encoding the gamma region of IMP731or a biologically active fragment thereof.

Another embodiment is directed to a polypeptide encoded by nucleic acidmolecule composing a nucleic acid sequence encoding the gamma region ofIMP731 or a biologically active fragment thereof.

Another embodiment is directed to an antibody that binds LAG-3 proteinand depletes LAG-3⁺ activated T cells and comprises a light chainvariable region comprising the 3 CDRs in FIG. 22 and a heavy chainvariable region comprising the 3 CDR's in FIG. 23.

Another embodiment of the invention is directed to a method ofidentifying a molecule that binds LAG-3 protein and may deplete LAG-3⁺activated T cells, the method comprising providing an assay in which acandidate molecule and IMP371 compete for binding on an LAG-3 protein,wherein when said candidate blocks IMP371 from binding said LAG-3protein. said candidate is identified as a molecule that binds LAG-3protein and may deplete LAG-3⁺ activated T cells.

Another embodiment of tne invention is directed to a method of assessinga candidate molecule for cytotoxicity on LAG-3⁺ activated T cells, themethod comprising incubating T-cells in a CMV peptide containing mediumwith the candidate molecule and under the same conditions, incubatingT-cells in a CMV peptide containing medium without the candidatemolecule and comparing the percentage of T cells expressing anactivation marker with the candidate molecule against the percentage ofT cells expressing an activation markers without the candidate molecule,wherein a reduction in the percentage of activated T-cells with thecandidate molecule indicates the cytotoxicity of the candidate moleculeon LAG-3⁺ activated T cells.

DESCRIPTION OF THE FIGURES

FIG. 1: LAG-3 mRNA expression in cardiac allograft (A), in the spleen(B) and in lymph nodes (C). Expression of LAG-3 mRNA in heart grafts atday 5 was measured by quantitative RT-PCR and compared with housekeepingHPRT transcripts expression. Rejection: allograft without treatment.Syngenic: isograft. Tolerant: allograft in recipients receiving atolerogenic (CsA+anti-CD28 antibodies) treatment. **; p<0.05 forsyngenic and tolerant vs. rejection.

FIG. 2: Characterization of anti-LAG-3 antibodies in acomplement-dependant cytotoxicity assay. ConA-stimulated target cellswere labeled with ⁵¹Cr and mixed with rabbit complement and anti-LAG-3(full line) or preimmune (dotted line) serum at the indicated dilution.% cytotoxic activity is calculated as follows: (CPM of theassay—spontaneous CPM release)/maximum released CPM obtained after celllysis.

FIG. 3: In vitro depleting activity of anti-LAG-3 antibodies. T cellsfrom the spleen were activated for 48 h with Con A to induce expressionof LAG-3 and labeled with CFSE. 10⁶ cells were injected i.v torecipients that had been irradiated (4.5 Gy) 3 days before. Twenty-fourhours after injection, recipients were sacrificed and the presence ofCD4⁺ cells in the CD8⁺ and CD8⁻ compartments of the spleen analysed byflow cytometry.

FIG. 4: Heart graft survival after anti-LAG-3 antibodies administrationLew. IA recipients of fully allogeneic (class I and II mismatch) Lew. 1Whearts were treated by injections on days 0 and 3 of 200 ul (dashedline) or 600 μl (full line) rabbit anti-LAG-3 serum or of 600 μlpre-immune serum (dotted line). Graft survival was evaluated by dailyevaluation of heartbeat P<0.002 for 600 μl rabbit anti-LAG-3 serum vs.pre-immune serum.

FIG. 5: Analysis of Graft infiltrating cells (GICs) GICs were extractedfrom cardiac allografts on day 5 from control-treated or anti-LAG-3antibodies treated recipients. Cells were counted and analyzed by flowcytometry for the expression of LAG-3. White bars: total number of GICs.Black bars: LAG-3⁺ GICs measured by flow cytometry (p<0.01). Total RNAwas also extracted from GICs and messenger for INFγ were quantified byqPCR, relative to HPRT expression level (dashed bars; p<0.05).

FIG. 6: Comparison of A9H12 binding with the reference LAG-3 specific17B4 mAb on LAG-3+CHO and activated human T cells.

A) hLAG-3-transfected CHO were dissociated from culture plastic usingVersene buffer containing cation-chelating agent, incubated withindicated concentrations of A9H12 or

17B4 mAbs for 30 min at 40 C, washed and then incubated with aFITC-conjugated goat anti-mouse IgG+M (H+L) secondary antibody (5 μg/ml,Coulter) for 30 minutes at 4° C. After washing, cells were analysed byflow cytometry using a FACSCanto (BD Biosciences) and means offluorescence intensity were plotted as a function of antibodyconcentration.

B) PBMCs from a healthy volunteer were stimulated for 2 days with SEB (1μg/ml, Sigma Aldrich) to induce the expression of LAG-3 on T cells.PBMCs were stained as above. Data represent a weighted percentage,calculated as the percentage of LAG-3+ cells in PBMCs×mean offluorescence intensity of the LAG-3+ cells, plotted as a function ofantibody concentration.

FIG. 7: Complement-Dependent Cytotoxicity induced by A9H12 LAG-3 mAb.

A) hLAG-3-transfected and wild type CHO cells were labelled withFITC-conjugated anti-LAG-3 mAb (17B4) and the expression of LAG-3 oncell surface was analysed by flow cytometry using a FACSCanto. Thehistogram plots represent the mean fluorescence intensity of wt CHO(gray) and LAG-3⁺ CHO (dark).

B) hLAG-3-transfected and wt CHO cells were washed in complete medium(MEM supplemented With 10 % heat inactivated Foetal Call Serum, FCS) andincubated with 0.1 μg/ml of A9H12 LAG-3 mAb or mIgG2a isotype-controlmAb (Southern Biotechnologies) in complete medium for 30 min at 4° C.Cells were then washed and incubated in complete medium (−Complement) orin MEM supplemented wtth 10 0 of freshly resuspended rabbit serum(Cerdalane Inc.) (+Complement) for 1 hour at 37° C. After washing, cellswere stained with 7-AAD (Coulter Inc.) for 15 minutes at roomtemperature and immediately analysed by flow cytometry to determined thepercentage of 7-AAD-positive cells corresponding to dead cells. Datarepresent the percentage of dead cells in each condition onhLAG-3-transfected and wt CHO cells as indicated.

C) LAG-3 CHO cells were incubated with indicated concentrations of A9H12LAG-3 mAb for 30 min at 4° C. and then incubated with MEM supplementedwith 25 % rabbit serum for 1 hour at 37° C. After washing, cells werestained with 7-AAD (Coulter Inc.) and analysed by flow cytometry. Thepercentage of specific cytotoxicity is calculated according to thefollowing formula

(Sample Death—Spontaneous Death)×100

(Maximal Death—Spontaneous Death)

where Sample Death is the percentage of 7-AAD-positive cells in eachcondition. Spontaneous Death, the percentage of 7-AAD positive cellswithout mAb and Maximal Death, the percentage of 7-AAD-positive cellswith 10 μg/ml mAb.

D) LAG-3⁺ CHO cells were incubated with 0.1 μg/ml A9H12, 17B4 or 31G11LAG-3 mAb or wth their corresponding isotype controls (IgG2a, IgG1 orIgM, respectively) for 30 min at 4° C. and then incubated with MEMsupplemented with 25% rabbit serum for 1 hour at 37° C. Specificcytotoxicity was determined as above with a Maximal Death correspondingto 10 μg/ml A9H12 (left panel) and 0.1 μg/ml A9H12 (right panel).

E) PBMCs were stimulated with SEB (1 μg/ml) to induce LAG-3 expressionon T cells and then used as target cells in the CDC assay in thepresence of A9H 12 or 31G11 LAG-3 mAb or their isotype controls. Afterstaining cells with fluorochrome-conjugated CD3, CD4, CD8, CD25 and17B4, the percentage of 7-AAD-positive cells was analysed on theindicated T cell subpopulations. Data represent the percentage of deadcells in each population (with spontaneous death in the absence of mAbbeing subtracted).

FIG. 8: Antibody-Dependent Cell-mediatec Cytotoxicity induced by A9H12LAG-3 mAb

A) Effector cells (PBMCs) were stimulated with IL-2 (100 IU/ml, BDBiosciences) for 1 day. Target cells (hLAG-3-transfected CHO cells) werelabelled with CFSE (a fluorescent vital dye) and incubated with 1 μg/mlA9H12, mIgG2a, 17B4 or mIgG1 for 20 min at room temperature. Effectorcells and target cells were then mixed at indicated E:T ratios (E:T,Effector:Target) and incubated for 16 hours at 37° C. Non-adherent andadherent cells were harvested using Versene reagent, stained with 7-AADand immediately analysed by flow cytometry to determine the percentageof 7-AAD-positive cells in the CFSE-positive population. Data representthe percentage of dead cells, with the non-specific cell death in thepresence of the isotype control being subtracted.

B) CFSE-labelled wild-type or LAG-3⁺ CHO target cells were incubatedwith indicated concentrations of A9H12 or mIgG2a and IL-2stimulatedPBMCs were added at a 50:1 E:T ratio and incubated for 16 hours at 37°C. Cell death was analysed as above and data represent tne percentage ofdead cells in CFSE-positive cells in the presence of A9H12 or itsisotype-matched IgG2a control mAB.

FIG. 9: Incidence of arthritis (percentage of mice that developed CIA)

Male DBA/1 mice (n=22) were injected i.d with bovine type II collagen(200 μg) emulsified in CFA containing 250 lug M. tuberculosis.

FIG. 10: Construction of the chimeric IMP731 therapeutic antibody.

FIG. 11: Expression plasmids for the light (panel A) and heavy (panel B)IMP731 chains.

FIG. 12: Final bi-cistronic plasmid construction used for the stabletransfection of CHO cells.

FIG. 13: IMP731 binding on LAG-3+ CHO and activated human T cells

A) hLAG-3-transfected CHO were dissociated from culture plastic usingVersene buffer containing cation-chelating agent, incubated withindicated concentrations of IMP731 Ab or its isotype control hIgG1(Chemicon) for 30 min at 4° C., washed and then incubated with aFITC-conjugated F(ab)′2 goat anti-human IgG1 secondary antibody (5μg/ml, SBA) for 30 minutes at 4° C. After washing, cells were analysedby flow cytometry using a FACSCanto (BD Biosciences) and the means offluorescence intensity were plotted as a function of antibodyconcentration.

B) PBMCs from a healthy volunteer were stimulated for 2 days wiih SEB (1μg/ml Sigma Aldrich) to induce the expression o LAG-3 on T cells. PBMCswere stained as adove. Data represent a weighted percentage, calculatedas the percentage of LAG-3⁺ cells in PBMC ×mean of fluorescenceintensity of the LAG-3⁺ cells, plotted as a function of antibodyccncentration.

FIG. 14: Complement-Dependent Cytotoxicity induced by IMP731 LAG-3 mAb

hLAG3-transfected CHO cells were incubated with 1 μg/ml of IMP731 Ab orhIgG1 isotype-control mAb (Chemicon) in complete medium (MEMsupplemented with 10 % heat inactivated Foetal Calf Serum, FCS) for 30min at 4° C. Cells were then washed and incubated in complete medium(without Complement) or in MEM supplemented with 25% of freshlyresuspended rabbit serum (Cerdalane Inc.) (with Complement) for 1 hourat 37° C. After washing, cells were stained with 7-AAD (BD Biosciences)for 15 minutes a room temperature and immediately analysed by flowcytometry to determine the percentage of 7-AAD-positive cellscorresponding to dead cells. Data represent the percentage of dead cellsin each condition as indicated.

FIG. 15: Antibody-Dependent Cell-mediated Cytotoxicity induced by IMP731.

A) Effector cells (PBMCs) were stimulated with IL-2 (100 IU/ml, BDBiosciences) for 1 day. Target cells (hLAG-3-transfected CHO cells) werelabelled with CFSE (a fluorescent vital dye) and incubated with 1 μg/mlIMP731 or hIgG1 for 10 min at room temperature. Effector cells andtarget cells were then mixed at indicated E:T ratios (E:T,Effector:Target) and incubated for 16 hours at 37° C. Cells were stainedwith 7-AAD and immediately analysed by flow cytometry to determine thepercentage of 7-AAD-positive cells in the CFSE -positive population.Data represent the percentage of dead cells.

B) CFSE-labelled LAG-3 CHO target cells were incubated with indicatedconcentrations of IMP731 or hIgG1 and IL-2-stimulated PBMCs were addedat a 50:1 E:T ratio and Incubated for 16 hours at 37° C. Cell death wasanalysed as above in CFSE-positive population. The percentage ofspecific cytotoxicity, calculated according to the following formula

(Sample Death−Spontaneous Death)×100

Maximal Death−Spontaneous Death)

where Sample Death is the percentage of 7-AAD-positive cells in eachcondition, Spontaneous Death, the percentages of 7AAD-positive cellswithout Ab and Maximal Death, the percentage of 7-AAD-positive cellswith 1 μg/ml IMP731.

C) Effector cells (PBMCs) were stimulated with IL-2 (100 IU/ml, BDBiosciences) for 1 day. Target cells (hLAG-3⁺ CHO cells or hLAG-3⁻ CHOcells) were labelled with CFSE (a fluorescent vital dye) and incubatedwith 1 μg/ml IMP731 or hIgG1 for 10 min at room temperature. Effectorcells and target cells were then mixed at indicated E:T ratios (E:T,Effector:Target) and incubated for 16 hours at 37° C. Cells were stainedwith 7-AAD and immediately analysed by flow cytometry to determine thepercentage of 7-AAD-positive cells in the CFSE-positive population. Datarepresent the percentage of dead cells.

FIG. 16 depicts ADCC activity of IMP731 using CMV peptides-activatedhuman T cells. This ADCC assay was performed with PMBCs from aCMV-positive human donor stimulated with a CMV peptide pool. Variousconcentrations of IMP31 or human IgG1 were added for 4 hr. Then, thecells were phenotyped to evaluate the percentage of activated T cellsremaining. The dose-dependent decrease of the percentage of activatedCD8⁺ (panel A, left) or CD4⁺ (panel A, right) T cells expressing LAG-3induced by IMP731 versus its isotype-matched hIgG1 control) ispresented. Panel B presents the percentage of CD3⁺CD8⁺ and CD3⁺CD4⁺cells expressing CD25 and/or LAG-3 with 10-ng/ml of IMP731 or hlgG1.

FIG. 17 depicts the pharmacokinetics of IMP731 injected into 3 baboons(0.1 mg/kg).

FIG. 18 depicts DTH reaction as a model for psoriasis inflammation inbaboon. Two BCG vaccines were injected before the 5^(th) DTH to test thelong-term IMP731 depletion effect on tuberculin-specific memory T cells.

FIG. 19 depicts the size of the DTH reaction of three baboons to a full(1:1 dilution) or a suboptimal tuberculin dose (1/50 dilution). Opensymbols show the first reference DTH dark symbols the subsequent DTHperformed after i.v. injection of 0.1 mg/kg of IMP731. IDR meansintra-dermal reaction.

FIG. 20 are DNA and amino acid sequences for the light chain kapparegion of IMP731, inducing the variable reason sequences and the aminoacid sequences for CDR-L1, -L2 and -L3.

FIG. 21 are DNA and amino acid sequences for the heavy chain gammaregion of IMP731, including the vanable region sequences and the aminoacid sequences for CDR-H1, -H2 and -H3.

FIG. 22 shows the characterization of variable and signal peptidesequences of the kappa chain from IMP731 recombinant antibody. FR,Framework; CDR, Complementarity Determining Region.

FIG. 23 shows the characterization of variable and signal peptidesequences of the gamma chain from the IMP731 recombinant antibody. FR,Framework; CDR. Complementarity Determining Region.

DETAILED DESCRIPTION

The present invention provides molecules binding to LAG-3 protein andcausing depletion of LAG-3+ activated T cells. Said depletion can bemeasured by changes in peripheral blood lymphocyte numbers, a tissue oran organ.

The present invention relates preferably to human LAG-3 protein (hLAG-3also named hereafter LAG-3). In a preferred embodiment the moleculebinding to LAG-3 protein is a cytotoxic anti-LAG-3 monoclonal antibodyor fragment thereof causing depletion of LAG-3+ activated T cells, saidantibody comprising an Fc fragment from the human IgG1 or IgM (or mouseIgG2a) subclass and an Fab fragment which binds LAG-3 protein, saidantibody exhibiting a complement-dependant cytotoxicity (CDC) and/or anantibody dependant-cell cytotoxicity activity (ADCC).

Lymphocyte activation gene-3 (LAG-3, CD223) is up-regulated during theearly stages of T-cell activation. The present invention is based on theanalysis of the effects of cytotoxic antibodies against LAG-3 in acutecardiac allograft rejection and in rheumatoid arthritis (in vivo animalstudies) and in in vitro experiments where selected LAG-3 monoclonalantibodies are efficient at low doses (<0.1 μg/ml) at depleting LAG-3⁺activated effector T cells.

Fully vascularized heterotopic allogeneic heart transplantation wasperformed in rats across a full-MHC mismatch barrier (LEW. 1W into LEW.1A). Recipients received two injections (day 0 and 3) of antibodiesdirected to the extraloop domain of LAG-3 or control antibodies. Graftsurvival, histology, mRNA transcripts and alloreactivity of lymphocyteswere tested.

It was first noted that LAG -3 mRNA molecules accumulate in cardiacallografts undergoing rejection, but not in peripheral lymphoid organs.Administration of anti-LAG-3 antibodies inhibited graft infiltration byeffectors mononuclear cells and prolonged allograft survival from 6 daysin control antibodies-treated recipients to a median of 27 days.

It was found that cells expressing LAG-3 infiltrate rejected heartallografts and that targeting LAG-3 using cytotoxic antibodies asinduction monotherapy delays acute rejection by reducing graftinfiltration by T cells and monocytes.

Experiments showing that short courses of CD40L antibody therapy couldachieve long-term graft survival in mice and primates have beeninitially interpreted as an effect of costimulation blockade. However.Monk et al. (2) showed that much of the efficacy of anti-CD40L therapyderives not from costimulation blockade, but from destruction ofactivated T cells. The outcome is a selective purging of potentiallyaggressive T cells that have experienced antigen.

Collagen-induced arthritis (CIA) is a well-described animal model forrheumatoid arthritis. Collagen-induced arthritis is an autoimmunedisease inducible in rats, mice and primates by immunization withheterologous type II collagen. The resulting joint pathology resemblesrheumatoid arthritis with synovial proliferation, cell infiltration,cartilage erosion and bone resorption in the most severe cases (12).

Using particular immunization protocols early studies have established ahierarchy of responsiveness to CIA linked to the H-2 haplotype, withH-2^(q) (e. g. DBA/1 mice) being the most and H-2^(b)(e.g. C57/BL/6mice) amongst the least responsive strains. However, some studies haveshown that responsiveness to CIA may be less restricted by the MHC classII than previously thought and may be just as dependent on immunizationconditions (13). The variety of type II collagen (CII) from differentspecies and the preparation of complete Freund's adjuvant (CFA) withdifferent concentrations of Mycobacterium tuberculosis were importantparameters for arthritis development. Inglis et al. have shown thatchicken, but not bovine, CII was capable of inducing disease in C57BL/6mice, with an incidence of 50% to 75%. This is in contrast to DBA/1mice, in which bovine, mouse and chicken CII all induced disease, withan incidence of 80% to 100%. The phenotype of arthritis was milder inC57BL/6 mice than in DBA/1 mice, with less swelling and a more gradualincrease in clinical score (14). Moreover, male mice are frequentlypreferred for CIA studies, as the incidence of arthritis is somewhathigher in male than in female mice.

In mice, CIA is induced by an i.d. injection of type II collagen (CII)in the presence of CFA, usuallv followed by an i.p. boost injection ofCII, without adjuvant, 21 days later. However. there are reportedvariations for almost every aspect of the immunization procedure andeven in the highly susceptible DBA/1 strain the time of onset, seventyand incidence of CIA can be variable (13, 15).

Therapeutic antibodies for the treatment of auto-immune diseases havealready been described, like the TNFa mAbs in rheumatoid arthritis. Bydefinition, LAG-3 (Lymphocyte Activation Gene-3) is a marker forrecently activated effector T cells. Depleting these effector LAG-3+ Tcells will lead to targeted immunosuppression (i.e.) only activated Tcells are suppressed, not all T cells as with corticoids orcyclosporin). This very specific immunosuppression should lead to highertherapeutic indices compared to classical immunosuppressive agents or totherapeutic antibodies (e.g. Humira, Remicade) or soluble receptors(e.g. Enbrel) blocking TNFa. Thus, LAG-3 is a promising target availablefor a therapeutic depleting mAb approach to eliminate auto-reactiveactivated effector T cells.

Molecules that bind to LAG-3 protein and cause depletion of LAG-3-+activated T cells, according to the present invention, includeantibodies (mono or polyclonal, preferably monoclonal) and fragmentthereof, peptides and organic small molecules.

Cytotoxic anti-LAG-3 monoclonal antibody or fragment thereof accordingto the present invention causes depletion of more than 30% preferablymore than 50% of LAG-3+ activated T cells.

Cytotoxic anti-LAG-3 monoclonal antibody or fragment thereof accordingto the invention comprises antibodies a murine IgG2a or a human IgG1 Fcregion giving strong CDC or ADCC properties.

Cytotoxic anti-LAG-3 monoclonal antibody or fragment thereof accordingto the present invention exhibits (i) more than 50% of maximal CDCactivity at a mAb concentration of less than 0.1 μg/ml and/or (ii) morethan 50% of maximal ADCC activity at a mAb concentration of less than0.1 μg/ml.

Cytotoxic anti-LAG-3 monoclonal antibody or fragment thereof, whichsuppresses a DTH reaction in a mammal after a single dose of 0.1 mg/kg.

Molecules binding to LAG-3 protein and more particularly cytotoxicanti-LAG-3 monoclonal antibody, causing depletion ot LAG-3+ activated Tcells and antibody, can be produced by methods well known to thoseskilled in the art.

Antibodies generated against CD223 polypeptides can be obtained byadministering. In particular by direct injection, CD223 polypeptides toan animal, preferably a non-human. The antibody so obtained will thenbind the CD223 polypeptides itself. In this manner, even a sequenceencoding only a fragment of the CD223 polypeptide can be used togenerate antibodies binding the whole native CD223 polypeptide.

For preparation of monoclonal antibodies, any technique which providesantibodies produced by continuous cell line cultures can be used.Examples include the hybridoma technique (9), the trioma technique, thehuman B-cell hybridoma technique (10).

Techniques described for the production of single chain antibodies (U.S.Pat. No. 4,946,778) can be readily used to produce single chainantibodies to CD223 polypeptides. Also, transgenic mice may be used toexpress humanized antibodies to immunogenic CD223 polypeptides.

An antibody of the present invention includes intact antibodies, anantibody fragment, a humanized antibody, a conjugate, a fusion proteinor a bi-specific antibody that contains a V_(H)-V_(L) pair where theCDRs form the antigen binding site. The invention also includesantibodies in which the Complementarity Determining Region (CDRs) of oneof the antibodies of the invention, such as those set forth in FIGS. 22and 23, are transferred from the native framework (FR) to a differentFR. The antibody of the invention could be produced recombinantly,according to methods known in the art.

For instance, a first monoclonal antibody according to the presentinvention, called A9H12, is produced by the hybridoma deposited at theCNCM on Apr. 27, 2007 under the access number CNCM I-3755.

A second monoclonal antibody according to the present invention, called31G11, is produced by the hybridoma deposited at the CNCM on Apr. 27,2007 under the access number CNCM I-3756.

A third monoclonal antibody according to the present invention, calledIMP731, is produced by chimerization of monoclonal antibody A9H12 withhuman lgG1 Fc region, as described and characterized in Examples 4, 5and 6.

The antibodies of the present invention include those that have the sameCDRs as the above antibodies (A9H12, 31G11 or IMP731) but havedifferences due to glycosylation patterns or post translationalmodifications.

The invention is also directed to the use of a cytotoxic anti-LAG-3monoclonal antibody or fragment thereof for the manufacture of amedicament for treating or preventing organ transplant rejection or fortreating autoimmune disease.

Biologically active fragments of the monoclonal antibodies of thepresent invention exhibit some or all of the biological activities ofthe monoclonal antibody. For example, biologically active fragments ofIMP731 exhibit the same high binding affinity as IMP731, as assessed ina standard assay such as a Biacore analysis. Biological activity mayalso be assessed by other in vitro or in vivo assays, which are known tothe skilled artisan and which are used to assess and characterize themonoclonal antibodies of the invention. One such assay assesses DTHreaction in baboons. Another in vitro assay is the ADCC bioassaydescribed in Example 5 and FIG. 16 and related description. In oneembodiment, the invention relates to the ADCC assay described in Example5 and in FIG. 16 and to the use of such assay in identifying depletingLAG-3 antibodies or fragments thereof that have an EC50 of lees than 5ng/ml.

The present invention also relates to an antibody other than IMP731which comprises the kappa or gamma regions of IMP731 and which has thesame biological activity as IMP/731. In another embodiment, theinvention relates to antibodies or fragments thereof that compete withIMP731 in binding LAG-3 protein and in causing depletion of LAG-3⁺activated T cells.

The nucleic acid sequences encoding the kappa and gamma regions of IMP731 are set forth in FIGS. 20 and 21, respectively. The presentinvention includes these nucleic acid sequences and biologically activefragments and mutations thereof and nucleic acid molecules comprisingthese nucleic acid sequences, vectors comprising these nucleic acidmolecules, cells comprising such vectors and pharmaceuticals comprisingthe nucleic acid molecules of the invention. The present invention alsois directed to the polypeptides encoded by the nucleic acid molecules ofthe invention and particularly to polypeptides represented by the aminoacid sequences set forth in FIGS. 20 and 21, and also polypeptidescomprising such ammo acid sequences and biologically active fragmentsand mutations of such amino acid sequences. In one embodiment, theinvention is directed to molecules comprising the CDRs set forth inFIGS. 20 and 21 and further characterized in FIGS. 22 and 23 and tomolecules comprising such CDRs that may have minor amino acid deferencesfrom the native sequences, wherein such molecules have an EC50 of lessthan 5 ng/ml in the ADCC bioassay using CMV-stimulated human CD4 and CD8T cells.

The present invention further provides a method for treating orpreventing organ transplant rejection or for treating autoimmunedisease. Said method composes the administration to a mammalian subjecta therapeutically effective amount of a cytotoxic anti-LAG-3 monoclonalantibody or fragment thereof.

Organ transplant rejection refers to the graft of an organ in anallogenic host. It may be useful for treating organisms suffering fromconditions resulting in an abnormally high T-cell population ordeleterious T-cell activity, for example graft rejection mediated byhost T-cells, graft vs. host disease and T-cell mediated autoimmune andinflammatory diseases such as rheumatoid arthritis, type 1 diabetes,muscular sclerosis, etc. The methods of the invention may be applied toany organism which contains T-cells that express CD 223. This includes,but is not limited to any mammal and particularly includes humans andmice.

Autoimmune diseases are diseases in which the subject's own immunesystem reacts against the subject cells. Auto-immune disease which areamenable to treatments according to the present invention includeautoimmune nemolytic anemia, autoimmune thrombocytopenia purpura.Goodpasture's syndrome, pemphigus vulgaris, acute rheumatic fever, mixedessential cryoglobulinemia, systemic lupus erythematosus,insulin-dependent diabetes mellitus, rheumatoid arthritis, Grave'sdisease, Hashimoto's thyroiditis, myasthenia gravis, psoriasis andmultiple sclerosis.

A method for depleting LAG-3+ activated T cells from a sample from apatient according to the present invention comprises reacting the samplewith an antibody composition comprising an antibody described above.

A pharmaceutical composition according to the present inventioncomprises from 0.1 to 300 mg per dose, preferably from 0.5 to 30 mg perdose, and more preferably from 5 to 10 mg per dose, of a cytotoxicmonoclonal antibody described above and one or more pharmaceuticallyacceptable carriers, adjuvants and/or diluents for administration to amammal. In another embodiment, the pharmaceutical composition accordingto the invention comprises from 0.01 to 30 mg per kg, preferably from0.1 to 3 mg per kg, and more preferably from 0.5 to 1 mg per kg of thecytotoxic monoclonal antibody described above. One of skill in the artwould understand that the pharmaceutical compositions of the inventioncould be adjusted to contain amounts of the cytotoxic monoclonalantibody that would vary depending upon the health, age, weight, andcondition ot the subject being treated.

The pharmaceutical compositions of the present invention may bespecially formulated for administration in solid or liquid formaccording to methods well known to the skilled artisan. Suitablecarriers, for instance, vehicles, adjuvants, excipients and diluents arewell known to the skilled artisan. Suitable formulations includeformulations to oral, aerosol, parenteral, subcutaneous, transdermal,transmucosal, intestinal, intramedullary, intravenous, intranasal,intraocular, intravenous and interperitoneal administration or injectionare exemplary and are not intended to be limiting. Techniques forformulating the pharmaceuticals of the present invention may be found inRemington's Pharmaceutical Sciences 18^(th) ed. Mack Publishing Co.,Easton, Pa. (1990).

The pharmaceutical compositions of the invention may contain thecytotoxic monoclonal antibody of the invention in combination with oneor more other therapeutic agents.

The following examples further illustrate the invention but should notbe construed as limiting the scope of the invention.

EXAMPLE 1

LAG-3-Positive Cells Targeted with Cytotoxic Antibodies Material andMethods Animals and Transplantations

Eight- to 12-week-old male Lewis. 1W (LEW. 1W, haplotype RT^(a)) andLewis. 1A (LEW. 1A, haplotype RT^(a)) congeneic rats (Centre d'ElevageJanvier, Le Genest-Saint-Isle, France), differed in their entire MHCregion. Heterotopic LEW. 1W heart transplantation was performed aspreviously described (11). Graff survival was evaluated by palpationthrough the abdominal wall.

Anti-LAG-3 Antibodies

A synthetic peptide corresponding to the extraloop domain of the ratLAG-3 protein (NCBI accession nb DQ438937; peptideDQPASIPALDLLQGMPSTRRHPPHR) was linked to ovalbumin and used to immunisetwo rabbits. Pre-immune and immune sera, collected on day 63 after the4th immunisation, were assayed by ELISA on immunogen and peptide and byflow cytometry on Con-A activated rat spleen cells. Pre-immune sera werenegative in both assays. Pooled immune sera presented a titer (dilutionfor 50% signal) of 1/60000 by ELISA and of 1/1000 by FRCS, and presenteda specificity for activated T cells.

Complement-Dependant Cytotoxicity Assay

Complement-mediated antibody-dependent cytotoxicity was tested usingrabbit sera against Lewis 1A T cells in a ⁵¹Cr release assay. A total of2×10⁸ Lewis 1A T cells were labelled with 30 μCi of ⁵¹Cr for 90 min at37° C. in RPMI (GIBCO) with 10% FCS. After three washes, T cells weredistributed in 96 V-bottomed plates and incubated with rabbit complementand serial dilutions of heat-inactivated rabbit serum. After 4 h at 37°C, ⁵¹Cr release was measured in the supernatants using a scintillationcounter. Specific cytotoxicity was calculated according to the followingformula: (experimental release−spontaneous release)×100/(maximumrelease−spontaneous release).

In Vivo Antibody-Induced Cytotoxicity

Cytotoxic activity of anti-LAG-3 antibodies against LAG-3⁺ cells wasevaluated in vivo. ConA-activated (48 h) LEW. 1W splenocytes werelabelled with the CFSE and transferred (10⁸ cells) into irradiated (4.5Gy, day-3) LEW. 1A recipients, together with anti-LAG-3 antibodies. Onday 1, recipients were sacrificed and the presence of CFSE-positivecells evaluated by flow cytometry in lymphoid organs and in the blood.

Immunostaining

Graft samples were embedded in Tissue Tek (OCT Compound, Torrance,Calif., USA), snap-frozen in liquid nitrogen, cut into 5 μm sections andfixed in acetone. Endogenous biotin activity was blocked using the Dakobiotin blocking system (Dako, Trappes. France). Sections were thenlabelled by a three-step indirect immunoperoxidase revelation. The areaof each immunoperoxidase-labeled tissue section infiltrated by cells wasdetermined by quantitative morphometric analysis. Positively stainedcells on each slide were counted by morphometric analysis using pointcounting analysis (14) with a 121-intersection squared grid in theeyepiece of the microscope. Briefly, the percentage of the area of eachgraft section occupied by cells of a particular antigenic specificity(area infiltrate) was calculated as follows: [number of positive cellsunder grid intersection/total number of grid intersections=121)]×100.The graft sections were examined at a magnification of ×400. Theaccuracy of the technique is proportional to the number of pointscounted. Thus, to maintain a SE of <100, 15 fields were counted for eachlabeled section. Results are expressed as the percentage of the area ofthe tissue section infiltrated by leukocytes (determined with OX1, OX30labeling) and the phenotypic composition of the infiltrate andsubpopulations which are related to the percentage of total leukocytesand are expressed as the percentage of leukocytes.

Graft Infiltrating Cell Extraction Staining

Dilacerated hearts were digested with collagenase D (2 mg/ml; BoehringerMannheim) for 10 min at 37° C. Cells were then collected by extractionthrough a stainless steel mesh. The resulting suspension was thenclarified by Ficoll isolation.

Quantitative RT-PCR

Real-time quantitative PCR was performed in an Applied Biosystems GenAmp7700 Sequence Detection System using SYBR Green PCR Core Reagents(Applied Biosystems, Foster City, Calif.). The followingoligonucleotides were used in this study rat: LAG-3: upper primer is5′-ATATGAATTCACAGAGGAGATGAGGCAG-3′ and lower pomer is5′-ATATGAATTCTCCTGGTCAGAGCTGCCT-3′. Rat INFg, upper primer is5′-TGGATGCTATGGAAGGAAAGA-3′ and lower primer is5′-GATTCTGGTGACAGCTGGTG-3′-Rat HPRT; upper primer is51-CCTTGGTCAAGGAGTACAGCC-3′ and lower primer is5′-TTCGCTGATGACACAAACATGA-3′. A constant amount of cDNA corresponding tothe reverse transcription of 100 μg of total RNA was amplified in 25 Mlof PCR mix containing 300 nM of each primer; 200 μm dATP, dGTP dCTP; 400μM dUTP; 3 mM MgCl₂; 0.25 U of uracyl-N-glycosylase; 0.625 U of AmpilTaqGold DNA polymerase, The mix was subjected to 40 cycles ofamplification. The real-time PCR data were plotted as the ΔR_(n),fluorescence signal vs. the cycle number. The ΔR_(n) values werecalculated by the Applied Biostystems 7700 sequence detection softwareusing the formula: ΔR_(n)=(R_(n) ⁺)−(R_(n) ⁻), where R_(n) ⁺ is thefluorescence signal of the product at any given time, R_(n) ⁻ is themean fluorescence signal during cycles 3-13 and referred to as thebaseline. The Ct value is defined as the cycle number at which theΔR_(n) crosses a threshold. The threshold is set above the backgroundfluorescence to intersect the exponential portion of the amplificationcurve of a positive reaction. The Ct is inversely proportional to thelog amount of template within the PCR.

Statistical Analyses

Statistical significance was evaluated using as Mann-Whitney test forthe comparison of two groups. Graft survival was evaluated byKaplan-Meier analysis using the log rank test.

Results

LAG-3 mRNA expression in rejected allograft and lymphoid organs LAG-3 isexpressed by activated T cells in inflamed lymphoid organs and tissues(7). In order to see if LAG-3 is also expressed in rejected allografts,hearts grafts from LEW. 1W to LEW. 1A rat recipients were analysed onday 5 (rejection occurring on day 6). Messenger RNA for LAG-3 wasanalyzed and compared with allografts receiving a tolerance-inducingregiment (anti-CD28 antibodies+CSA, as described (16) and withisografts. Rejected allografts presented a 7-fold and a 25-foldaccumulation of LAG-3 mRNA as compared with tolerated and syngeneicgrafts, respectively (FIG. 1A). Such an accumulation was not detected inlymph nodes (FIG. 1B) or in the spleen of rejecting recipients (FIG.1C).

Mechanism of Action of Anti-LAG-3 Antibodies

Anti-LAG-3 antibodies were produced in rabbits by immunization with asynthetic peptide from the extra-loop of LAG-3 Ig-like N-terminaldomain, involved in the interaction of LAG-3 with Class II (ref PNASHuard 1997). Post-immune serum, as well as the IgG fraction, stained <1%of rat spleen cells and 400 of rat spleen cells activated for 48 h withConA PMA+ionomycin or PHA. Pre-immune serum was negative (data notshown). In order to characterize the effect of anti-LAG-3 antibodies onLAG-3⁺ cells, complement and ADCC-dependant cytotoxicity was assayed invitro. Fifteen % of ConA-activated spleen cells were lysed in thecomplement-dependant cytotoxicity assay (FIG. 2). Given that only 400 ofthe ConA-activated target cells expressed LAG-3, this assay revealedthat about 37 a of the LAG-3⁺ spleen cells present in the preparationwere lysed in vitro as a result of complement activation.

In vivo, the depleting activity of anti-LAG3 antibodies was estimated bymeasuring the fate of CFSE-labeled activated T cells adoptivelytransferred to irradiated rat recipients. One day after the injection oftherapeutic doses of anti-LAG-3 immune serum, only half the amount ofCFSE⁺/CD4⁺ and CFSE⁺/CD8⁺ cells could be recovered from the spleen, ascompared with similar injections of pre-immune serum (FIG. 3).

Anti-LAG-3 Antibodies Delay Heart Allograft Rejection

From preliminary pharmacokinetic observations, we established that twoi.v. injections of 600 μl of anti-LAG-3 rabbit serum on days 0 and 3resulted in the maintenance of anti-LAG-3 binding activity inrecipient's serum for at least 2 weeks. This treatment delayed cardiacallograft rejection from 6 days in untreated and control-treatedrecipients to a median of 27 days. All recipients, however, eventuallyrejected their graft within 10 weeks (FIG. 4). On day 5, grafts fromcontrol-treated recipients were heavily infiltrated by activated T cellsand this infiltrate was less important in anti-LAG-3 treated recipients.Infiltration by CD25⁺ cells and NK cells, however, was not modified bythe treatment. Since our anti-LAG3 antibodies do not recognize LAG-3 inimmunohistology, LAG-3 expression by graft infiltrating cells (GICs) wasanalyzed by flow cytometry after extraction. An average of 8.5 10⁶±0.76GICs could be recovered from control rejected grafts. From heartallografts from anti-LAG-3 treated recipients, only 3.16±0.44 10⁶ GICscould be recovered (n=3; p<0.005). GICs contained 41.17±1% LAG-3⁺ cellsin controls (i.e. 3.5 10⁸ cells) versus 22.2±0.9% in treated animals(i.e. 0.7 10⁶ cells, n=3; p<0.0005; FIG. 5). Analysis of mRNA transcriptreinforced these observations that infiltration of heart graft bymononuclear cells was reduced since we measured four times less INFγmRNA molecules in treated grafts (FIG. 5).

Anti-LAG-3 Antibodies Inhibit Ongoing Acute Heart Allograft DelayRejection

In order to investigate whether anti-LAG-3 antibodies might serve as atreatment of an ongoing acute allograft rejection, we grafted LEW. 1Whearts into LEW. 1A allogenic recipients that we maintained untreatedover 3 or 4 days. At that time, recipients received an injection of 600microliter of control or anti-LAG-3 rabbit serum. Control-treatedrecipients rejected the allografts on day 5 whereas anti-LAG-3antibodies-treated recipients rejected only on day 11 (Table 1).

TABLE 1 Treatment Day of rejection Median survival Control serum on day3 5, 5, 5 5 Control serum on day 4 5, 5, 5 5 Anti-LAG-3 serum on day 312, 13, 9 12 (p < 0.05 vs. control) Anti-LAG-3 serum on day 4 10, 13,13, 19 12.5 (p < 0.05 vs. control)

Table 1: Heart graft recipients were treated on day 3 or 4 with controlor anti-LAG-3 antibodies. Rejection was monitored by daily heartpalpation.

EXAMPLE 2 Generation of New High Affinity hLAG-3 mAbs Material andMethods

Mice were immunized 3 times with hLAG-3-transfscted CHO cells (10⁷cells, intra-peritoneal injection), followed by a boost i.v. injectionwith 10 μg IMP321, the clinical-grade hLAG-31 g recombinant protein.Three days after the boost, splenocytes were fused with the X63 AG8653fusion partner to yield hybridoma cells. Supernatants from hybridomaswere screened for their specific binding (FACS analysis) onhLAG-3-tranfected CHO versus wild type (wt) CHO cells.

One murine IgG2a antibody (580. 1E, MM H12, called A9H12) was selected,subcloned to yield a stable cell line and further characterized for itspotency to deplete LAG-3⁺ cells through CDC (complement-dependentcytotoxicity) and ADCC (antibody-dependent cell-mediated cytotoxicity),given that the murine IgG2a Pc region is known to be the most efficientFc isotype in mice at delivering these activities, even on heterologouscells (i.e. CHO cells or human PBMCs. Similarly, a second IgM antibody(31G11E8, called 31G11) was also selected.

Results

Dose-dependent binding of A9H12 was first compared to the referenceLAG-3-specific 17B4 mAb on hLAG-3-transfected CHO cells and on LAG-3⁺ invitro activated human T cells (FIG. 6) A9H12 displayed a greater bindingthan the reference 17B4 mAb on both cell types. For instance,significant binding of A9H12 to activated human T cells was observedwith a concentration as low as 0.01 μg/ml.

For CDC testing, the target cells used in this assay were LAG-3⁺ CHOcells compared to wt CHO cells (FIG. 7A). Both types of cells wereincubated for 1 hour at 37° C. with either A9H12, its murineisotype-matched IgG2a negative control mAb, 31G11, its murineisotype-matched IgM negative control or the reference 17B4 (IgG1) mAband rabbit serum containing active complement. Cell viability was thenassessed using 7-Amino-Actinomycin D (7-AAD), a fluorescent dyelabelling cells which have lost their membranous integrity, a phenomenonwhich appeared rapidly after death. The percentage of 7-AAD-positive CHOcells (i.e dead target cells) was determined by flow cytometry analysis.A9H12 displayed a potent and specific cytotoxic activity in this CDCassay, killing only LAG-3⁺CHO cells in the presence of complement (FIG.7B). The anti-LAG-3 Ab was titered down to determined the efficacy ofthe antibody to activate CDC at low concentration of antibody A9H12efficiently induced LAG-3⁺ CHO cells killing at a concentration as lowas 0.01 μg/ml (FIG. 7C). The IgG1 17B4 antibody was also tested in thisassay and had no effect (FIG. 7D, left panel), showing that not allLAG-3 mAbs could induce cytotoxicity in this bioassay. As observed withA9H12, the second 31G11 LAG-3-specific mAb also induced LAG-3⁺ CHO cellskilling (FIG. 7D, right panel).

The CDC bioassay was also performed on PBMCs stimulated with thesuperantigen SEB. The cytotoxicity of A9H12 and 31G11 were analysed onboth activated (namely CD25⁺/LAG-3⁺ cells) and non-activated (namelyCD25⁻/LAG-3⁻ cells) CD4⁺ helper T and CD8⁺ cytotoxic T cells. Onlyactivated CD4⁺ and CD8⁺ T cells were specifically killed by A9H12 and31G11 (FIG. 7E), showing that activated human T cells are susceptible toA9H12-or 31G11-specific killing in the presence of complement.

For ADCC testing, PMBCs were stimulated for one day with IL-2 to serveas effector cells and LAG-3⁺ CHO cells were labelled with the vital dyeCFSE to serve as target cells. In the presence of A9H12, PBMCs were ableto kill a significant percentage of LAG-3⁺ CHO cells and this effect wasincreased with the number of effector cells. (FIG. 8A). In the presenceof 17B4, only a small percentage of target cells was killed even at ahigh E:T ratio (FIG. 8A), showing that not all LAG-3 mAbs could inducecytotoxicity in this bioassay. The A9H12 LAG-3 mAb was titered down todetermine the efficacy of the antibody to induce ADCC at lowconcentration of antibody. A9H12 efficiently induced LAG-3⁺ CHO cellskilling at a concentration as low as 0.01 μg/ml (FIG. 8B).

EXAMPLE 3 Testing Depleting LAG-3 Antibodies in a Collagen-InducedArthritis Mouse Model Material and Methods Animals and Materials

Male DBA/1 (H-2^(q)) mice, 8-10 weeks old, were obtained from JanvierLaboratories. All animal experiments were performed according to localguidelines. Bovine CII (joint cartilage) was puchased from BioCol.Incomplete Freund's adjuvant was provided by Sigma. Heat-killed M.tuberculosis H37Ra was purchased from Difco Laboratories.

Induction of Collagen-Induced Arthritis (CIA)

The induction and assessment of CIA were performed as previouslydescribed in two publications (13, 15). Complete freund's adjuvant wasprepared by mixing 100 mg heat-lilled Mycobacterium tuberculosis in 13.3 ml IFA (final concentration 7.5 mg/ml) Bovine CII was dissolved at 3mg/ml in 10 mm acetic acid overnight at 4° C. An emulsion was formed bymixing 2 volumes of CII with 1 volume of CFA. The CII solution and theemulsion with CFA were always freshly prepared. Male DBA/1 mice wereintra-dermally injected at the base of the tail with a total of 100 μlof emulsion containing 200 μg CII and 250 μg M. tuberculosis on day 1(D1). The injection was repeated at day 21 (D21). As control, three micewere injected with the emulsion of CFA without CII.

Clinical Assessment of Arthritis

Mice were examined for signs of arthniiS three times a week from day 22.The disease severity was determined with the following scooring systemfor each limb; score 0=normal; score 1=swelling of footpad or joint;score 2=swelling of footpad and 1 or 2 joints; score 3=swelling offootpad and 3 or 4 joints; score 4=swelling of footpad and all joints.Each paw was graded, and the 4 scores were summed so that the maximumpossible score was 16 per mouse. Incidence was expressed as thepercentage of mice with an arthritis score≧1.

Results

CIA was induced by i.d. injections of bovine type II collagen (CII)emulsified in CFA containing 250 μg M. tuberculosis. After oneinjection, 4 out of 22 mice had developed arthritis at D21. Two weeksafter the second injection, at D35, 80-90% of the mice had developedclinical signs of arthritis (FIG. 9). The mice exhibited clinical scorescovering the full range of responses from 1 to 16 with some limbsshowing severe swelling of the footpad, ankle /wrist joint and digits(Table 2). None of the control animals (injected with CFA without CII)developed signs of arthritis (data not shown).

TABLE 2 Days Mean SEM 25 2.2 0.9 27 2.7 0.8 29 5.7 1.0 32 9.2 1.5 3410.5 1.5 36 10.9 1.6 39 10.8 1.7 41 10.9 1.6 43 11.2 1.5 46 11.7 1.3 5313.1 1.2 55 13.3 1.1

Table 2: Mean clinical scores (±SEM) over 55 days. Male DBA/1 mice(n=10) were injected i.d. with bovine type II collagen (200 mg)emulsified in CFA containing 250 mg M. tuberculosis at D1 and D21.

Our results show that with the CIA protocol used, it is possible toobtain a high percentage (80-90%) of mice developing signs of arthritis.This experimental protocol provides a model to evaluate the therapeuticeffect of depleting LAG-3 antibodies (specific for mouse LAG-3) inauto-immune diseases.

200 μg of the depleting LAG-3 mAb (A9H12 or 31G11) are injected i.p. ori.v. on day 15 and 25. Both a significant decrease in arthritisincidence and a significant lowering of mean clinical scores areinvolved.

EXAMPLE 4 Complement-Dependent Cytotoxicity (CDC) and Antibody-DependentCell-Mediated Cytotoxicity (ADCC) Induced by IMP731 Materials andMethods

A new murine mAb with depleting properties, A9H12, has been shown torecognize also baboon and macaque monkey LAG-3³⁰ cells with high avidityand had been chosen as our lead depleting therapeutic mAb (ImmuTuneIMP731).

A9H12 has been chimerized with a human IgG1 Fc region using standardgenetic engineering and PCR protocols, to give CDC (complement-dependentcytotoxicity) and ADCC (antibodydependent cell cytotoxicity) properties.

The A9H12 VH and VL cDNA sequences derived from A9H12 hybridoma cellmRNA were fused upstream of the human CH1-hinge-CH2-CH3 IgG1 domains andCkappa chains, respectively (FIG. 10).

The two light and heavy IMP731 chimeric chains were independently clonedinto separate expression plasmids (FIG. 11 panel A and B, respectively)under the control of the PGK (or SRalpha in another construction, notshown) promoter. These 2 plasmids were cotransfected (transitorytransfection) together into CHO cells and IMP731 was purified from theculture supernatant at day 2 or 3 by using protein A column affinitycapture and elution at pH 3. After neutralisation with Tris-HC1 thepurified IMP731 antibody was tested in CDC and ADCC experiments for itsability to kill LAG-3⁺ target cells.

The two IMP731 light and heavy chains were then cloned together with thePGK (or SRalpha, not shown) promoter in a head-to-tail situation forcoordinated expression of the two IMP731 chains from the sameintegration site (FIG. 12). This bi-cistronic IMP731 expression plasmidwas used for stable transfection and selection of high-productivity(e.g. more than 20 picogramme IMP731 protein per million CHO-S cells perday) CHO-S cells using increasing concentrations of hygromycine inserum-free medium.

The DNA and protein sequences dor the kappa region of IMP731 are setforth in FIG. 20 and the DNA and protein sequences for the gamma regionof IMP731 are set forth in FIG. 21.

Results

Dose-dependent binding of IMP731 was first assessed on hLAG-3-tranfectedCHO cells (FIG. 13A) and on LAG-3⁺ in vitro activated human T cells(FIG. 13B). IMP731 displayed a significant binding on both cell typeswith a concentration as low as 0.01 μg/ml for activated T cells.

For complement dependent cytotoxicity (CDC) testing, the target cellsused in this assay were LAG-3⁺ CHO cells (FIG. 14). Cells were incubatedeither with IMP731 or its human isotype-matched IgG1 negative controland then with rabbit serum containing active complement for 1 hour at37° C. Cell viability was then assessed using 7-Amino-Actinomycin D(7-AAD). 7-AAD is a fluorescent dye labelling cells which have losttheir membranous integrity, a phenomenon which appeared rapidly afterdeath. The percentage of 7-AAD positive CHO cells (i.e. dead targetcells) was determined by flow cytometry analysis. IMP731 displayed apotent and specific cytotoxic activity in this CDC assay, killing onlyLAG-3⁺ CHO cells in the presence of complement (FIG. 14).

For antibody-dependent cell-mediated cytotoxicity (ADCC) testing. PBMCswere stimulated for one day with IL-2 to serve as effector cells andLAG-3⁺ CHO cells were labelled with the vital dye CFSE to serve astarget cells. In the presence of IMP731, PBMCs were able to kill a highpercentage of LAG-3⁺ CHO cells (FIG. 15A). IMF731 LAG-3 Ab was titereddown to determine the efficacy of the antibody in inducing ADCC at lowconcentration of antibody. IMP731 significantly induced LAG-3⁺ CHO cellskilling at a concentration as low as 0.01 μg/ml (FIG. 15B). LAG-3⁺ butnot LAG-3⁺ cells were killed by the addition of IMP731 in this assay(FIG. 15C).

It appeared that binding and functional activities of IMP731 weresimilar to the parental A9H12 murine mAb produced by hybridoma cells.For instance, IMP731 has the same high affinity as the parent antibody,as assessed by Biacore analysis.

Antibodies: ka (1/Ms) kd (1/s) KD (M) Chi2 A9H12 1.72 × 10⁸ 1.43 × 10⁻³8.29 × 10¹⁰  8.65 IMP731 2.03 × 10⁶ 1.12 × 10⁻³ 5.51 × 10⁻¹⁰ 11.4(chimeric A9H12)

EXAMPLE 5 Antibody-Dependent Cellular Cytotoxicity (ADCC) of LAG-3⁺Human T Cells Activited by a Recall Antigen Peptide Pool Using theIMP731 Therapeutic Antibody Introduction

More than 80% of the population is cytomegalovirus (CMV) seropositiveand more than 50% has a high frequency of circulating CMV-reactive Tcells that can be analyzed in short-term in vitro assays in response toa CMV protein recall antigen. This is therefore a convenient setting inwhich to analyze IMP731-dependent antibody-dependent cellularcytotoxicity (ADCC) on subsets of antigen-specific T cellsphysiologically activated through peptide-dependent T-cell receptortriggering, using defined synthetic peptides (i.e. no antigeniccontaminants) from the sequence of a CMV protein.

In addition, this experimental setting mimics closely the situationencountered in auto-immune diseases where circulating antigen-specific Tcells are periodically stimulated by auto-immune recall antigens. Forexample in the case of psoriasis, the recall antigens are skin antigensthat are presented to the immune system in the form of MHC-class I- andclass II-restricted peptides.

Purpose

To assess the potency of IMP731 in killing activated antigen-specifichuman T cells stimulated with a CMV peptide pool and thus to estimatethe lowest dose likely to have a pharmacological effect in man.

Expermental Design

PBMCs from CMV-positive donors were thawed, washed in complete RPMI 1640supplemented with 10% FCS and seeded at 10⁶/ml in 24-well plate (1.75ml/well) in the presence of a CMV peptide pool (BD Biosciences). The CMVpeptide pool consists of a mix of 138 15-mers with 11 amino acidoverlaps spanning the entire sequence of the pp65 protein (CMV AD169strain). This peptide pool wll induce MHC class II-restricted CD4peptide-specific T cel activation and proliferation but will alsoactivate MHC class I restricted CD8 peptide-specific T cells through theinternalization and processing of 15-mers into 9-mers. Together theentire T cell repertoire specific for the pp65 protein will beactivated. The final concentration of each peptide was 0.875 μg/ml. Thecells were incubated at 37° C. for 5 days. As CD8 T cells proliferatemore rapidly than CD4 T cells, there will always be more CD8 than CD4activated T cells at day 5.

For ADCC testing, the cells were seeded in a 96-well U-bottom plate (180μl/well, containing 150-175×10 ³ cells/well) in the CMVpeptide-containing medium and 20 μl of 10× dilutions of IMP731 or itsisotype-matched control (human IgG1. Chemicon) were added. After 4 hr at37° C, the cells were stained with CD3-PE. CD4-PE-Cy7, CD8-APC-Cy7,CD25-APC (all from BD Biosciences) and FITC-conjugated anti-LAG-3 mAb(17B4 antibody, 1 μg/point) for 30 min at 4° C. After centrifuging, thecells were suspended for 15 min at room temperature in culture mediumcontaining 2.5 μl 7-AAD (viability dye), before FACS analysis. Afterexclusion of dead cells based on size/granularity and 7-AAD staining,the percentages of LAG-3⁺ and CD25⁺ (another T cell activation marker)in the CD3⁺CD4⁺ and the CD3⁺CD8⁺ cells populations were analysed.

Results

The stimulation of PBMCs with the CMV peptide pool induced theexpression of the activation marker CD25 and LAG-3 (see FIG. 16) on avariable percentage of CD8⁺ T cells (from 3 to 12% of T cells, 2 blooddonors tested in different experiments) and CD4⁺ T cells (lowerpercentages). In the presence of IMP731, the percentage of activatedCD8⁺ and CD-4⁺ T cells was dramatically reduced. A 70% reduction in thenumber of LAG-3⁺ cells was observed both in the CD4 and the CD8 subsetsat a 10 ng/ml IMP731 concentration (see FIG. 16, panel A). Similarresults have been obtained at least twice in two donors. Additionally,the half maximal effective concentration (EC50) was found to be 1±0.4ng/ml for CD4⁺ T cells and 0.7±0.4 ng/ml for CD8⁺ T cells (mean±sd of 5experiments).

The observed effect is not due to a competition between IMP731 and theanti-LAG-3 17B4-FITC reagent since the binding of 17B4-FITC is notinhibited by a 3-fold excess of IMP731 (not shown). A putativeinternalization of the membrane LAG-3 induced by IMP731 was alsoexcluded because the disappearance of activated T cells was alsoobserved with an anti-CD25 antibody (see FIG. 16B). Note that half ofCD25⁺ cells are LAG-3⁺ (in the CD4 subset, these cells are the naturalTregs) and are therefore not depleted. The depletion of CD25⁺ celsversus LAG-3⁺ cells is also minimized by the fact that many LAG-3⁺ cellsare CD25⁻ (not shown).

Conclusions

IMP731 efficiently induced cell-mediated cytotoxicity of activatedantigen-specific CD4 and CD8 human T cells at very low doses (1-10ng/ml). From previous work we know that a concentration of 30 ng/mlIMP731 was measured at t=116 hr in the baboon injected with 0.1 mg/kgIMP731 (experiment showing a long-term suppression of DTH reaction).Therefore the concentration in the first few hours must have been muchhigher.

Based on this information, it is believed that a starting dose in humanin the planned Phase Ia trial of 0.01 mg/kg could be pharmacologicallyactive. It is possible that even such a very low dose could lead to <10ng/ml serum concentration levels for a few hours and therefore besufficient to deplete LAG-3⁺ T cells in patients.

EXAMPLE 6 IMP731 DTH Studies in Baboons

IMP731 has been shown to be immunosuppressive after a single i.v. lowdose (0.1 mg/kg) injection on a skin antigen-specific reaction (DTH) inbaboon. This test is used as a surrogate in vivo assay for psoriasisinflammation. By continuing the DTH testing for five months after theinjection of IMP731 it was possible to show that the immunosuppressionwas long-lasting corresponding to the “Campath Effect”.

The choice of psoriasis as an initial indication is supported by thework showing that psoriatic skin is massively infiltrated with LAG-3⁺ Tcells compared to normal skin. The following describes the work whichled to these results and conclusions.

IMP731 suppresses DTH Reaction in Baboons

The half-life in 3 baboons injected (i.v.) with 0.1 mg/kg IMP731 showedsimilar pharmoklnetic profiles with the following elimination half-life,16, 21 and 31 hours (FIG. 17).

Delayed Type Hypersensitivity (DTH) reaction is an established model forskin inflammation (16-18). To assess the potency of IMP 731 on skintissue and their draining lymph nodes in baboons as a surrogate assayfor the treatment of psoriasis lesions, 3 baboons were immunized withtuberculin and then their reactivity was assessed in atuberculin-specific DTH reaction (see protocol in FIG. 18). In a DTHreaction the erythema (the reddened area of skin) measurement reflectsan antigen-specific CD4 and CD8 T cell response over time.

Even a single dose as low as 0.1 mg/kg IMP731 is immuno-suppressive asshown for Baboon #3 (FIG. 13) where the DTH is abrogated at a suboptimaldose (1:50 dilution) of tuberculin and is still inhibited in time andintensity at an optimal dose (1:1 dilution) of tuberculin. The relevanceof the DTH results is clear. Both psoriasis and DTH are caused byantigen-specific LAG-3⁺ activated T cells in the skin.

Decrease in LAG-3⁺ T Cells in Lymph Nodes

To quantify the systemic deletion of circulating LAG-3⁺ T cellsfollowing injection of IMP731, the number of LAG-3⁺ T cells in the DTHsite draining lymph nodes 3 days after the tuberculin injection wasanalyzed. The mean percentage of live LAG-3⁺ cells in theseimmune-reactive lymph nodes was 3.5% for the first DTH and only 0.7% forthe second DTH. This clearly indicates that IMP731 had killed 80% ofLAG-3⁺ cells in the antigen-reactive lymph node at day 3. This mechanismof action explains why the immunosuppressive effect on the DTH islong-lasting (see below).

IMP731 Still Suppresses DTH Reaction in Baboons Five Months AfterInjection

This immunosuppressive effect is sustained over time as a third, fourthand fifth DTH reaction performed up to five months after the IMP731injection is still inhibited (FIG. 19). This clearly shows that theeffect of antigen-specific immunosuppression is still as potent fivemonths after the injection of IMP731. This effect is made even morestriking by the fact that whereas IMP731 can easily be detected in theblood in the few days following injection, two months later there are nodetectable antibodies remaining.

IMP731 Suppresses DTH Reaction for Five Months Even After Two BoosterImmunizations

This long duration of immunosuppressive effect was tested to determinewhether ii might be due to the deletion of tuberculin-specific memory Tcells at the time of IMP731 injection. This is a possibility becauseCD45⁺ memory T cells (in both CD4 and CD8 subsets) are LAG-3⁺ in human.If so, the DTH would be suppressed following booster immunization.Accordingly, Baboon #3 was injected with two BCG vaccines beforeperforming the 5^(th) DTH (FIG. 18). Remarkably, the DTH was stilltotally negative (FIG. 19).

It is established that memory T cells may take up to a year to recoverfrom deletion in human (the “Campath Effect”) (19). Therefore, it islikely that psoriasis patients can be treated with a low dose (e.g. 0.1mg/kg) IMP731, which could be effective at deleting the activated memoryT cells.

REFERENCES

-   1. Waldmann H. The new immunosuppression, just kill the T cell. Nat    Med 2003; 9 (10): 1259.-   2. Monk N J, Hargreaves R E, Marsh J E, et al. Fcdependent depletion    of activated T cells occurs through CD40L-specific antibody rather    than costimulation blockade Nat Med 2003; 9 (10):1275.-   3. Andre P, Prasad K S, Denis C V, et al. CD40L stabilizes arterial    thrombi by a beta3 integrin-dependent mechanism. Nat Med 2002; 8    (3): 247.-   4. Avice M N, Sarfati M, Triebel F, Delespesse G, Demeure C E,    Lymphocyte activation gene-3, a MHC class II ligand expressed on    activated T cells, stimulates TNF-alpha and IL-12 production by    monocytes and dendritic cells, J. Immunol. 1999; 162: 2748.-   5. Andreae S, Piras F, Burdin N, Triebel F, Maturation and    activation of dendritic cells induced by lymphocyte activation    gene-3 (CD223) J Immunol 2002; 168 (8): 3874.-   6. Andreae S, Buisson S, Treibel F. MHC class II signal transduction    in human dendritic cells induced by a natural ligand, the LAG-3    protein (CD223). Blood 2003, 102 (6) 2130.-   7. Treibel F. LAG-3: a regulator of T-cell and DC responses and its    use in therapeutic vaccination. Trends Immunol 2003; 24 (12): 619.-   8. Macon-Lemaitre L, Triebel F. The negative regulatory function of    the lymphocyte-activation gene-3 co- receptor (CD223) on human T    cells. Immunology 2005; 115 (2): 170.-   9. Kohler and Milstein, Continuous cultures of fused cells secreting    antibody of predefined specificity. Nature. 1975; 256 (5517);    495-497.-   10. Kozbor et al., 1985, in Monoclonal Antibodies and Cancer    Therapy, Alan R. Liss, Inc., pp. 77-96-   11. Ono et al, Improved technique of heart transplantation in    rats. J. Thorac. Cardiovasc Surg. 57, 225-229.-   12. Stasiuk et al, Collagen-induced arthritis in DBA/1 mice.    Cytokine gene activation following immunization with type II    collagen. Cellular Immunol 1996; 173: 269-275.-   13. Campbell et al, Collagen-induced arthritis in C57BL/6 (H-2b)    mice, new insights into an important disease model of rheumatoid    arthritis. Eur. J. Immunol. 2000; 30: 1568-1575.-   14. Inglis. et al, Collagen-induced arthritis in C57BL/6 is    associated with a robust and sustained T-cell response to type II    collagen. Arthritis Research & Therapy. 2007; 9: R113.-   15. Hiroaki et al, A tumor necrosis factor receptor loop peptide    mimic inhibits bone destruction to the same extent as anti-tumor    necrosis factor monoclonal antibody in lurine collagen-induced    arthritis arthritis & Rheumatism. 2007; 56 (4): 1164-1174.-   16. Galli, S. J., and I. Hammel 1984. Unequivocal delayed    hypersensitivity in mast cell-deficient and beige mice. Science 226:    710.-   17. Lange-Asschenfeldt, B., W. Weninger, P. Velasco, T. R.    Kyriakides, U. H. von Andrian, P. Bornstein, and M. Detmar. 2002.    Increased and prolonged inflammation and angiogenesis in    delayed-type hypersensitivity reactions elicited in the skin of    thrombospondin-2-deficient mice. Blood 99:538.-   18. Kunstfeld, R., S. Hirakawa, Y. K. Hong, V. Schacht, B.    Lange-Asschenfeldt Velasco, C. Lin, E. Fiebier, X. Wei, Y. VVu, D.    Hicklin, P. Bohlen, and M. Detmar, 2004. Induction of cutaneous    delayed-type hypersensitivity reactions in VEGF-A transgenic mice    results in chronic skin inflammation associated With persistent    lymphatic hyperplasia. Blood 104:1048., P.-   19. Coles, A. J. et al, 2008 Alemtuzumab vs. interferon beta-1a in    early multiple sclerosis. N. Engl. J. Med. 359: 1786.

All references, including publications, patent applications and patentscited herein are hereby incorporated by reference, as if each wereindividually and specifically indicated to be incorporated by referenceand were set forth in its entirety herein.

1-18. (canceled) 19) A monoclonal antibody or a biologically activefragment thereof, wherein the monoclonal antibody or the biologicallyactive fragment thereof is capable of depleting LAG-3+ activated T cellsin a complement dependent cytotoxicity (CDC) assay and/or in anantibody-dependent cell cytotoxicity (ADCC) assay, and comprises: a) alight chain variable region comprising a CDR-L1 having the amino acidsequence as set forth in SEQ ID NO: 17, a CDR-L2 having the amino acidsequence of FAS, and a CDR-L3 having the amino acid sequence as setforth in SEQ ID NO: 18, and a heavy chain variable region comprising aCDR-H1 having the amino acid sequence as set forth in SEQ ID NO: 19, aCDR-H2 having the amino acid sequence as set forth in SEQ ID NO: 20, anda CDR-H3 having the amino acid sequence as set forth in SEQ ID NO: 21,or b) a light chain variable region and a heavy chain variable regionwith minor amino acid differences from the light chain variable regionand heavy chain variable region of (a). 20) A monoclonal antibody orbiologically active fragment thereof according to claim 19, wherein themonoclonal antibody or biologically active fragment thereof comprises anFc fragment from human IgG1, human IgM or mouse IgG2a. 21) A monoclonalantibody or biologically active fragment thereof according to claim 19,wherein the monoclonal antibody or biologically active fragment thereofhave an EC50 of less than 5 ng/mL in an ADCC assay. 22) A monoclonalantibody or biologically active fragment thereof according to claim 21,wherein the monoclonal antibody or biologically active fragment thereofhave an EC50 of less than 5 ng/mL in an ADCC assay comprisingCMV-stimulated human CD4 and CD8 T cells. 23) A monoclonal antibody orbiologically active fragment thereof according to claim 19, wherein themonoclonal antibody or biologically active fragment thereof comprises:a) a light chain variable region as set forth in SEQ ID NO:9 and a heavychain variable region as set forth in SEQ ID NO: 11, or b) a light chainvariable region and a heavy chain variable region with minor amino aciddifferences from the light chain variable region and heavy chainvariable region of (a). 24) A monoclonal antibody or biologically activefragment thereof according to claim 19, wherein the monoclonal antibodyor biologically active fragment thereof comprises: a) a light chainkappa region as set forth in amino acids 21 to 240 of SEQ ID NO: 13 anda heavy chain gamma region as set forth in amino acids 20 to 465 of SEQID NO: 16, or b) a light chain kappa region and a heavy chain gammaregion with minor amino acid differences from the light chain kapparegion and heavy chain gamma region of (a). 25) An isolated nucleic acidmolecule comprising a nucleic acid sequence encoding a monoclonalantibody or biologically active fragment thereof according to any ofclaims 19 to
 24. 26) A pharmaceutical composition comprising themonoclonal antibody or biologically active fragment thereof according toany one of claims 19 to 24